Peter F Lebowitz Receives Stock Award at BridgeBio Oncology Therapeutics Inc (BBOT) — SEC Form 4, Mar 26, 2026

SEC Form 4 · No Market Transaction

Stock Award

Compensation grant — no market purchase or sale.

Reporting Owner

Peter F Lebowitz

Director

TXN 2026-03-24 · FILED 2026-03-26

Filing Lag 2 business days within 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

BridgeBio Oncology Therapeutics Inc

BBOT CIK 0001869105

Reporting Owner

Name	Relationship
Peter F Lebowitz CIK 0002121402	Director

Peter F Lebowitz at BridgeBio Oncology Therapeutics Inc Full insider history

Bought (12 mo) —

Sold (12 mo) —

More from this insider at BridgeBio Oncology Therapeutics Inc

Award

—

View

Derivative Securities Transactions

Title	Strike	Date	Type	Shares	Price	Expiration	Underlying	Ownership
Stock Option (Right to Buy)F1	$8.72	2026-03-24	A - Award/Grant	63,350 A	$0.00	2036-03-23	63,350 Common Stock	Direct

Footnotes (1)

F1: 1/36th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 24, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Show more

5%+ Holders · 13D/G 7 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at BridgeBio Oncology Therapeutics Inc

GET /v1/forms/4/0001193125-26-126602 API docs